RADNOR, PA — Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) announced that the United States Patent and Trademark Office (USPTO) recently granted a new method of use patent for intravenous (IV) ganaxolone in the treatment of status epilepticus (SE), expiring in 2040.
The USPTO issued U.S. Patent No. 11,679,117, covering the clinical dosing regimen administering ganaxolone for SE patients, including those with refractory and super refractory status epilepticus. This is Marinus’ second method of use patent granted for IV ganaxolone in SE, broadening the dosing regimen and further strengthening the Company’s intellectual property position.
“The issue of this patent, along with other recent allowances granted by the USPTO, is an important milestone in protecting the commercial potential of ganaxolone,” said Scott Braunstein, M.D., Chairman and Chief Executive Officer of Marinus. “This achievement allows for broad investment in our IV franchise and demonstrates our unwavering dedication to preserving the innovative strength of our portfolio.”
Corresponding patent applications are expected to be filed in several other key global markets and additional novel applications are pending for IV ganaxolone in SE in the U.S.